NICE says Pradaxa equals Xarelto's efficacy for blood clots
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment institute for England and Wales, has given Boehringer Ingelheim's Pradaxa (dabigatran etexilate) the green light for use on the NHS to treat and prevent blood clots. The final draft guidance noted that no significant differences were found between Pradaxa and its competitor Xarelto (rivaroxaban) in terms of efficacy or cost.